MCK Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q3

FY2026Q4

FY2027Q1

105.98B

+11.22%

9.275

+15.51%

101.45B

+11.7%

11.286

+11.52%

105.80B

+8.15%

9.757

+18.13%

Estimates Revision

The market is revising Downward the revenue expectations for McKesson Corporation (MCK) for FY2026, with the revenue forecasts being adjusted by -0.04% over the past three months. During the same period, the stock price has changed by 7.79%.

Revenue Estimates for FY2026

Revise Downward

-0.04%

In Past 3 Month

EPS Estimates for FY2026

Revise Upward

+1.02%

In Past 3 Month

Stock Price

Go Up

+7.79%

In Past 3 Month

14 Analyst Rating

Wall Street analysts forecast MCK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MCK is 928.73 USD with a low forecast of 856.00 USD and a high forecast of 1000.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

12 Buy

2 Hold

0 Sell

Strong Buy

Current: 0.000

Low

856.00

Averages

928.73

High

1000.00

Current: 0.000

Low

856.00

Averages

928.73

High

1000.00

Deutsche Bank

George Hill

Buy

maintain

$861 -> $904

2025-12-10

Reason

Deutsche Bank

George Hill

Price Target

$861 -> $904

2025-12-10

maintain

Buy

Reason

Deutsche Bank analyst George Hill raised the firm's price target on McKesson to $904 from $861 and keeps a Buy rating on the shares. The company reiterated plans to exit the its med-surgical business segment through an initial public offering, followed by a spin-off or split-off, with the separation being complete by the end of 2027, the analyst tells investors in a research note. The firm says that while the transaction is likely dilutive, the stock "can still perform through the transaction."

Barclays

Overweight

initiated

$960

2025-12-08

Reason

Barclays

Price Target

$960

2025-12-08

initiated

Overweight

Reason

Barclays initiated coverage of McKesson with an Overweight rating and $960 price target. The firm started the U.S healthcare technology and distribution industry with a neutral view. Barclays is most bullish on the drug distributors and has a more mixed view of the dental and healthcare information technology sub-sectors.

Wells Fargo

Equal Weight

maintain

$816 -> $914

2025-11-10

Reason

Wells Fargo

Price Target

$816 -> $914

2025-11-10

maintain

Equal Weight

Reason

Wells Fargo raised the firm's price target on McKesson to $914 from $816 and keeps an Equal Weight rating on the shares. The firm is updating its model following Q2 2026 earnings and increasing its tests following core pharma distribution and prescription technology strength.

Mizuho

Neutral

maintain

$770 -> $880

2025-11-07

Reason

Mizuho

Price Target

$770 -> $880

2025-11-07

maintain

Neutral

Reason

Mizuho raised the firm's price target on McKesson to $880 from $770 and keeps a Neutral rating on the shares.

Baird

Eric Coldwell

Outperform

maintain

$873 -> $927

2025-11-06

Reason

Baird

Eric Coldwell

Price Target

$873 -> $927

2025-11-06

maintain

Outperform

Reason

Baird analyst Eric Coldwell raised the firm's price target on McKesson to $927 from $873 and keeps an Outperform rating on the shares. The firm updated its model following Q2 results.

UBS

Buy

maintain

$920 -> $980

2025-11-06

Reason

UBS

Price Target

$920 -> $980

2025-11-06

maintain

Buy

Reason

UBS raised the firm's price target on McKesson to $980 from $920 and keeps a Buy rating on the shares.

Valuation Metrics

The current forward P/E ratio for McKesson Corp (MCK.N) is 20.01, compared to its 5-year average forward P/E of 14.67. For a more detailed relative valuation and DCF analysis to assess McKesson Corp 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

14.67

Current PE

20.01

Overvalued PE

18.01

Undervalued PE

11.33

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

11.16

Current EV/EBITDA

15.16

Overvalued EV/EBITDA

13.56

Undervalued EV/EBITDA

8.77

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

0.18

Current PS

0.24

Overvalued PS

0.21

Undervalued PS

0.14

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

MCK News & Events

Events Timeline

No data

News

4.5

01-06NASDAQ.COM

USMV ETF Hits 52-Week High of $95.59, Last Trade at $94.40

9.5

01-06Benzinga

Lockheed Martin Shares Rise 2.9% Following U.S. Operation Against Maduro

4.5

2025-12-30Yahoo Finance

McKesson (MCK) Target Price Raised to $904 Amid Spin-Off Plans

People Also Watch

Frequently Asked Questions

What is McKesson Corp (MCK) stock price today?

The current price of MCK is 814.63 USD — it has decreased -1.13 % in the last trading day.

What is McKesson Corp (MCK)'s business?

McKesson Corporation is a diversified healthcare services company, which focuses on advancing health outcomes for patients everywhere. Its U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products in the United States (U.S.). The Prescription Technology Solutions (RxTS) segment helps solve medication access, affordability and adherence challenges for patients by working across healthcare to connect patients, pharmacies, pharmacy benefit managers, health plans, and biopharma companies. The Medical-Surgical Solutions provides medical-surgical supply distribution, logistics, and other services to healthcare providers, including physician offices, hospital reference labs, and home healthcare agencies. The International segment provides distribution and services to wholesale, institutional, and retail customers in Canada and Norway. It also offers oncology and specialty solutions.

What is the price predicton of MCK Stock?

What is McKesson Corp (MCK)'s revenue for the last quarter?

McKesson Corp revenue for the last quarter amounts to 103.15B USD, increased 10.14 % YoY.

What is McKesson Corp (MCK)'s earnings per share (EPS) for the last quarter?

McKesson Corp. EPS for the last quarter amounts to 8.92 USD, increased 379.57 % YoY.

What changes have occurred in the market's expectations for McKesson Corp (MCK)'s fundamentals?

How many employees does McKesson Corp (MCK). have?

McKesson Corp (MCK) has 43000 emplpoyees as of January 08 2026.

What is McKesson Corp (MCK) market cap?

Today MCK has the market capitalization of 101.70B USD.